sh-Polypeptide-4 for Hair Regrowth

Evidence Review created on 08/25/2026 using AI4L / Grok 4.5

Also known as: Recombinant Human Stem Cell Factor, rhSCF, SCF, KIT Ligand, Steel Factor, Mast Cell Growth Factor, CG-SCF, Ancestim, r-metHuSCF, Stemgen

Motivation

sh-Polypeptide-4 is a laboratory-made copy of a human signaling protein called stem cell factor. Cosmetic serums list it as a growth-factor copy. The natural protein tells pigment cells, hive-driving immune cells, and some follicle cells to survive and move. Follicle biology has shown that the control center of thinning, pale hairs releases less of this protein than the control center of thicker, pigmented hairs. That gap is why it is of interest.

Stem cell factor was cloned around 1990 and developed as an injected drug to move blood-forming cells, not to treat baldness. Those injection studies found extra pigment cells in the skin and emptying of the cells that drive hives and allergic swelling. Cosmetic makers later placed a laboratory-made version in leave-on scalp formulas, often mixed with other laboratory growth-factor copies, without a trial that counted scalp hairs.

This review examines whether replacing that missing follicle signal with topical sh-Polypeptide-4 has a credible hair-regrowth effect, what the injected-drug studies show about pigment cells and hive-driving immune cells, and how delivery and hive-reaction biology shape the picture for adults already using demanding hair protocols.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article for sh-Polypeptide-4 was found.

Examine

No Examine.com article for sh-Polypeptide-4 was found.

ConsumerLab

No ConsumerLab article for sh-Polypeptide-4 was found.

Systematic Reviews

No systematic reviews or meta-analyses for sh-Polypeptide-4 were found on PubMed as of 25 August 2026. Neither the claimed hair-density effect nor the principal mast-cell risk is represented by a systematic review.

Mechanism of Action

sh-Polypeptide-4 is a laboratory-made copy of human stem cell factor (SCF), the protein that binds KIT (CD117, a catalogue number for this receptor), a receptor tyrosine kinase (a cell-surface on/off switch) on pigment cells, mast cells, blood-forming progenitors, and some mouse hair-matrix keratinocytes. Ligand binding pairs KIT and turns on phosphoinositide 3-kinase/Akt and mitogen-activated protein kinase pathways (cell-survival and growth signals).

In the follicle, the dermal papilla (the control center at the bulb) secretes SCF. That local signal keeps bulb melanocytes (pigment cells) alive and making melanin during anagen (the growth phase) and moves melanocyte precursors. Papilla cells from human pattern-thinning follicles secrete less SCF than non-thinning cells (Randall et al., 2008), a proposed reason they look paler. Blocking KIT strips pigment from regenerating mouse hair and cultured human follicles; the bleaching is reversible.

A competing claim is that epithelial KIT also drives the growth cycle. Kit-impaired mice enter anagen more slowly. Mice that cannot make SCF still grow white hair. Pigmentation is the more robust SCF-dependent readout; shaft production leans on Wnt (a developmental growth signal), vascular endothelial growth factor (VEGF), and insulin-like growth factor 1 (IGF-1).

Cosmetic sh-Polypeptide-4 is typically an Escherichia coli–made ~18.5 kDa non-glycosylated chain. Intact skin poorly admits proteins this size, so leave-on papilla delivery is unproven. It is broken down by proteases, not cytochrome P450 enzymes (the liver enzymes that break down many drugs). Injected doses were once daily; topical follicular half-life is unmeasured.

Historical Context & Evolution

Steel and Dominant white-spotting mouse mutants, studied through the twentieth century, mapped to the genes for stem cell factor and KIT. Human SCF was cloned around 1990. Amgen developed recombinant methionyl human stem cell factor (r-metHuSCF; ancestim, brand Stemgen) as a subcutaneous injection to mobilize blood-forming cells, usually with granulocyte colony-stimulating factor (G-CSF, a neutrophil-stimulating protein). Phase I oncology series in the mid-1990s unexpectedly showed injection-site melanocyte hyperplasia (extra pigment cells) and anaphylactic-type mast-cell degranulation (sudden emptying of mast-cell granules) (Costa et al., 1996; Grichnik et al., 1995). Those findings are the actual human pharmacology of the protein, not later dismissals of it.

Ancestim saw limited use because allergic reactions required antihistamine premedication and because later mobilizing agents were easier to tolerate. It was not developed as a hair drug. Cosmetic suppliers, including Korean peptide houses that market CG-SCF, later listed recombinant SCF under the International Nomenclature of Cosmetic Ingredients (INCI) name sh-Polypeptide-4, with labeled functions of hair conditioning, skin conditioning, and antioxidant—not as an approved alopecia treatment. Academic follicle work from Bradford and others then showed that balding human papilla cells secrete less SCF (Randall et al., 2008), which is the scientific bridge from pigment biology to pattern thinning. Current cosmetic use stacks the protein in multi-factor serums; that commercial path has not produced a dedicated hair-count trial.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no randomized or replicated human trial has measured hair density, hair count, or another validated hair-growth endpoint after topical or injected sh-Polypeptide-4.

Medium 🟩 🟩

No benefit reaches Medium: human clinical findings for recombinant stem cell factor are open-label injection studies of pigment-cell and mast-cell endpoints, not hair-count outcomes.

Low 🟩

Hair and cutaneous pigment-cell support

In two open-label injection series, recombinant stem cell factor expanded skin melanocytes and darkened injection sites. KIT blockade bleaches regenerating hair in mice and cultured human follicles. Balding papilla cells secrete less SCF than non-balding cells—a tissue deficit, not a treatment result. Leave-on serums have not reproduced it.

Magnitude: 5 of 10 people in a 14-day subcutaneous recombinant SCF series developed persistent local hyperpigmentation (Costa et al., 1996). A second injection series showed melanocyte hyperplasia at SCF sites without a published 5-of-10 figure (Grichnik et al., 1995). KIT-neutralizing antibody caused reversible depigmentation of cultured human hair without a published percentage for topical SCF replacement (Hachiya et al., 2009). Balding papilla SCF deficit is a tissue finding, not a replacement percentage (Randall et al., 2008).

Speculative 🟨

Increased scalp hair density

No human trial has counted scalp hairs after sh-Polypeptide-4. The density claim is mechanistic or anecdotal only: an extrapolation from lower papilla SCF in pattern thinning, not a measured hair-count effect.

Anagen support via epithelial KIT

Kit-impaired mice enter anagen more slowly. Mice lacking SCF still grow white hair, so shaft production is less SCF-dependent than pigment. No human trial exists; the basis is mechanistic or anecdotal only.

Benefit-Modifying Factors

KITLG and KIT variants: Common KIT ligand (KITLG) polymorphisms shift hair color (Guenther et al., 2014). Loss-of-function KIT mutations cause piebaldism (unpigmented patches) (Ezoe et al., 1995). Those genotypes change the pigment-cell pool SCF can act on.
Baseline papilla SCF and pigment: Unpigmented follicles express less KIT. Replacement has more room where papilla SCF is low and some melanocytes remain (Randall et al., 2008; Hachiya et al., 2009).
Sex: Beard papilla cells secrete more SCF than scalp papilla cells in men. A uniform cosmetic dose is not sex-calibrated (Hibberts et al., 1996).
Pattern thinning versus other alopecias: The SCF-deficit story is from androgenetic alopecia (AGA, pattern thinning) papilla cultures. Alopecia areata (patchy autoimmune hair loss) has different drivers (Ashrafuzzaman et al., 2010).
Age: Unpigmented older follicles show lower KIT. Greying is the aging phenotype most tightly tied to this pathway; density loss has other causes (Hachiya et al., 2009).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mast-cell degranulation with wheal-and-flare (a raised itchy bump with surrounding redness) and anaphylactoid (anaphylaxis-like, non-allergic) reactions

Recombinant stem cell factor is also mast-cell growth factor. Subcutaneous pharmaceutical doses caused wheal-and-flare at every injection site, electron-microscopic anaphylactic-type degranulation, higher distant dermal mast-cell density, and rises in urinary methyl-histamine and serum tryptase (a mast-cell enzyme in blood). Hematology protocols used multi-agent antihistamine premedication for this class effect. Leave-on cosmetic exposure is unquantified and is likely much lower if the protein does not cross intact skin; the same protein, injected, is a documented mast-cell activator.

Magnitude: Wheal-and-flare occurred at each subcutaneous injection site in a 10-person 14-day recombinant SCF series; distant dermal mast-cell density and mast-cell mediators rose after the course (Costa et al., 1996; Dvorak et al., 1998). Local injection-site reactions were the most common adverse event in a separate 38-person r-metHuSCF plus filgrastim mobilization trial (Moskowitz et al., 1997).

Medium 🟥 🟥

No other risk reaches Medium: remaining human findings are uncontrolled injection-site observations, which are graded Low.

Low 🟥

Unwanted cutaneous hyperpigmentation

Injected recombinant stem cell factor expanded skin melanocytes and left persistent dark patches at injection sites in two open-label series. Leave-on cosmetic doses are unquantified. This is a pigment-cell effect, not a hair-density result.

Speculative 🟨

Promotion of KIT-driven cell clones

KIT signaling supports melanocytes and mast cells. Extra ligand could favor KIT-dependent clones such as moles, melanoma, or mastocytosis (a mast-cell overgrowth). No such signal is reported for topical cosmetic SCF; the concern is mechanistic.

Immunogenicity of E. coli recombinant protein

Cosmetic sh-Polypeptide-4 is typically fermented in E. coli. Residual host protein or a non-human N-terminal methionine (as in ancestim) can be immunogenic. No published antibody-rate data exist for topical serums; the basis is mechanistic.

Risk-Modifying Factors

KIT-activating mutations: The D816V KIT mutation in systemic mastocytosis fires the receptor without ligand. Extra SCF is redundant there and still expands other mast cells (Costa et al., 1996).
Baseline tryptase and atopy (allergic tendency): Higher mast-cell burden (raised tryptase; chronic urticaria (hives); poorly controlled asthma) enlarges the degranulation substrate that injected SCF used. Topical risk is unmeasured.
Sex: No dedicated sex-difference adverse-event analysis was published in the small oncology SCF series. Beard versus scalp SCF output differs; mast-cell event rates were not split by sex.
Pigment or mast-cell disease: Active melanoma, atypical moles on the field, or mastocytosis change the cost of melanocyte and mast-cell hyperplasia (Grichnik et al., 1995).
Age and barrier: Older, thinner, or microneedled scalp barrier may admit more protein. Oncology SCF series enrolled middle-aged and older adults with cancer, not healthy longevity users, so age-specific topical risk is unknown.

Key Interactions & Contraindications

KIT inhibitors (imatinib, sunitinib, barzolvolimab): Absolute pharmacologic antagonism of the intended receptor. Consequence: cancelled SCF signal and, for anti-KIT antibodies, intended mast-cell suppression. Severity: absolute contraindication.
Mast-cell secretagogues (opioids such as morphine, nonsteroidal anti-inflammatory drugs, vancomycin, radiocontrast): Caution; additive degranulation if SCF reaches dermal mast cells. Mitigation: extra caution around procedures that already trigger mast cells.
Histamine type 1 and 2 blockers (H1/H2 antihistamines: cetirizine, famotidine): Used as premedication with injected ancestim. Severity: mitigating. They blunt wheal-and-flare; they do not make cosmetic SCF a proven hair drug.
Other hair-growth actives (minoxidil, finasteride, dutasteride): No shared metabolic pathway. Mechanisms differ (vasodilation; 5-alpha-reductase (the enzyme that makes dihydrotestosterone)). Severity: monitor; stacks lack interaction trials.
Other topical growth-factor analogues (VEGF, keratinocyte growth factor, IGF-1 copies): Possible additive KIT-adjacent signaling and mast-cell tone. Severity: caution; doses in multi-factor serums are undisclosed.
Microneedling or ablative lasers: Increases protein delivery through a disrupted barrier and can itself degranulate mast cells. Severity: caution; this is how clinics often apply peptide cocktails (a systematic review of microneedling, English et al., 2022).

Populations who should avoid sh-Polypeptide-4:

Systemic mastocytosis, recurrent anaphylaxis, or poorly controlled chronic urticaria (injected SCF is a mast-cell growth and degranulation signal).
Active cutaneous melanoma or numerous atypical melanocytic lesions on the intended field (injection-site melanocyte hyperplasia is documented).
Known hypersensitivity to E. coli-derived proteins or to ancestim.
Pregnancy and lactation (KIT ligand is required for germ-cell biology; topical fetal data do not exist).
Open, infected, or highly inflamed scalp until the barrier is intact (higher absorption and more local mast cells).

Risk Mitigation Strategies

Leave-on intact scalp only: Avoid broken skin and elective barrier disruption unless a clinic protocol accepts higher delivery and mast-cell exposure; this limits systemic-like mast-cell activation.
Patch test on a small scalp area: Watch 24–48 hours for wheal, itch, or unexpected pigment before broader use; this screens for immediate mast-cell reactivity.
Avoid injectable gray-market SCF: Pharmaceutical doses caused universal wheal-and-flare; cosmetic INCI use is topical. Injection recreates the High-grade mast-cell risk.
Pause around KIT-targeted drugs: People using imatinib-class or anti-KIT biologics have a blocked receptor; adding ligand is futile and pharmacologically inconsistent.
Stop for wheal, itch, or unexpected darkening: Local wheal or new pigment is the injected-drug mast-cell and melanocyte signal; continuing would repeat that exposure.

Therapeutic Protocol

No established hair-density protocol: No named clinic has published an sh-Polypeptide-4–only regimen with hair counts. Cosmetic use is a leave-on serum, usually once or twice daily on a dry scalp.
Cosmetic concentrations are undisclosed: INCI lists presence, not micrograms per milliliter. Hematology used 5–20 µg/kg subcutaneously—a different route, not a hair dose (Moskowitz et al., 1997).
Timing: Once-daily evening application is typical for leave-on hair serums so the film stays put. Topical follicular half-life is unknown; injected pharmaceutical SCF was given once daily.
Split versus single application: No pharmacokinetic basis for splitting a topical dose. If used, a single daily leave-on film is the pattern in commercial serums.
Genetics and dose: No pharmacogenetic dose algorithm. KIT/KITLG pigment genotypes change the melanocyte pool, not a proven microgram dose.
Sex: Beard versus scalp SCF output differs in men; no sex-specific cosmetic dose exists. Female-pattern thinning has not been studied with this ingredient.
Age: Greying follicles may be the more biologically aligned target than long-bald scalp. No age-banded protocol exists.
Baseline status: Higher remaining density and residual pigment leave more KIT-positive cells to receive a signal. Smooth bald scalp has fewer follicles to rescue.
Pre-existing conditions: Pattern thinning is the only alopecia with a papilla-SCF rationale. Active mast-cell disease or a melanoma-prone field changes whether topical use is even considered.
Competing approaches: Conventional density tools (topical minoxidil, oral 5-alpha-reductase inhibitors) have hair-count trials. Clinic peptide mesotherapy (needle injection of mixed actives into the scalp) and microneedling are used empirically and mix many actives, so SCF’s share cannot be isolated.

Discontinuation & Cycling

Duration of use: Cosmetic serums are used continuously, not as a defined medical course. There is no evidence that lifelong application maintains density.
Withdrawal: No SCF-specific withdrawal syndrome is described. Injected-site pigment persisted after a 14-day recombinant SCF course; that is leftover melanocytes, not a withdrawal effect (Costa et al., 1996).
Taper: Not applicable for a topical protein with no receptor occupancy data on scalp. Stopping is abrupt in ordinary cosmetic use.
Cycling: No tachyphylaxis (fading effect with continued use) study exists. KIT can be internalized after ligand binding in other tissues; whether scalp cycling would preserve a hypothetical effect is unknown.
Return of miniaturization: If any density effect were real, it would be expected to fade over a hair-cycle after stopping, as with other non-curative follicle signals.

Sourcing and Quality

INCI identity: The listing to match is sh-Polypeptide-4, the recombinant SCF analogue—not “peptides,” sh-Oligopeptide-4 (a thymosin analogue), or unnamed “stem cell” extracts (COSMILE Europe monograph).
Recombinant source: Typical supply is E. coli fermentation (for example CG-SCF from Caregen-class vendors). Identity (protein-size gel or mass) and residual host-protein data are the relevant quality documents; most retail serums publish neither.
Stability: A soluble ~18.5 kDa protein is heat- and protease-labile. Cold storage after opening and short beyond-use windows matter more than for small-molecule minoxidil.
Multi-factor blends: Commercial hair serums rarely isolate sh-Polypeptide-4. Stacks prevent attributing change to this ingredient and hide the actual microgram dose.
Not a drug product: Ancestim/Stemgen was a regulated injection for cell mobilization, not a hair cosmetic. Gray-market “research” vials for injection are the high-risk form, not a quality upgrade.

Practical Considerations

Time to effect: Hair-cycle endpoints are read at 3–6 months. Injection-site darkening appeared during a 14-day recombinant SCF course, a pigment rather than a density timeline (Costa et al., 1996).
Common pitfalls: Treating a multi-factor serum as SCF monotherapy; confusing sh-Polypeptide-4 with sh-Oligopeptide-4; injecting cosmetic protein; expecting minoxidil-scale counts without a trial that measured them.
Regulatory status: In the EU it is a cosmetic INCI ingredient (hair conditioning, skin conditioning, antioxidant), not an authorized alopecia medicine. It is not approved by the Food and Drug Administration (FDA) to treat hair loss.
Cost: Specialty growth-factor serums cost more than generic topical minoxidil. Insurers covering minoxidil or finasteride but not cosmetic peptides have a systematic incentive to favor those reimbursed tools, a structural bias in guideline attention and research funding. Price is not evidence of a hair-count effect.
Delivery reality: Without microneedling, liposomes, or another proven carrier, an 18 kDa protein has little reason to reach the dermal papilla from intact scalp.

Interaction with Foundational Habits

Sleep: Direction: none directly. Poor sleep can trigger telogen (resting-phase) shedding on its own, which would swamp any unproven topical signal. No timing restriction versus sleep is known.
Nutrition: Direction: none directly. SCF is a protein ligand, not a nutrient. Follicle outcomes still depend on iron, protein, and energy availability. No SCF-specific depletion or food interaction is documented.
Exercise: Direction: none directly; androgens are an indirect modifier. No hypertrophy-blunting or workout-timing effect is known. Androgens reshape papilla SCF output, but this is not a studied training interaction (Hibberts et al., 1996).
Stress management: Direction: none directly; possible indirect overlap via inflammation. Psychological stress drives telogen shedding through other hormones. No cortisol-lowering claim is established for topical sh-Polypeptide-4.

Monitoring Protocol & Defining Success

Baseline, before a cosmetic trial, is a standardized global scalp photograph set plus, where available, a phototrichogram (camera count of hairs per square centimeter) at a marked site, with shaft-diameter sampling. Those measures define whether density or caliber moved. Blood tests are not required for ordinary leave-on use. If there is a mast-cell history, a baseline tryptase (a mast-cell enzyme in blood) gives a personal reference.

Ongoing checks sit at about 12 weeks and 24 weeks, then every 6 months if the product remains in a stack. Success is a rise in density or diameter versus that person’s own baseline. Unchanged miniaturization after two hair-cycle checkpoints means the ingredient has not moved the endpoint. Shed-hair counts, itch or wheals after application, and unwanted skin darkening are read monthly.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Hair density (phototrichogram)	Rise versus own baseline; no universal target	Objective hairs per area	Same site and lighting; 12 and 24 weeks
Hair shaft diameter	Rise versus own baseline	Tracks miniaturization	Pair with density; not a blood test
Global scalp photography	Documented change versus baseline	Real-world appearance	Fixed angles and hair length
Serum tryptase	Stay at personal baseline	Mast-cell burden if atopy or non-topical use	Mast-cell enzyme; conventional often <11 ng/mL; not needed for routine leave-on cosmetics; no fasting

Qualitative markers:

Shed-hair counts on pillow or drain versus the person’s pre-trial week.
Local itch, wheal, or flushing after application (mast-cell warning).
New or expanding dark patches on treated skin.
Perceived coverage at the part or crown on standardized photos.

Emerging Research

No registered hair trial: ClinicalTrials.gov searches for sh-Polypeptide-4, topical SCF, and ancestim in alopecia on 25 August 2026 returned no dedicated hair-density study. The terminated 32-person phase 2 lymphoma study NCT01016795 tested injected recombinant stem cell factor plus filgrastim for cell mobilization, not scalp density.
KIT blockade in humans: Anti-KIT antibodies such as barzolvolimab reduce urticaria by suppressing mast cells (Maurer et al., 2025). That live clinical path is the opposite of adding KIT ligand and could weaken a “more SCF is always better” reading.
Delivery engineering: Liposomal and microneedle carriers appear in patents and clinic practice because unmodified ~18 kDa SCF is a poor skin penetrant. Positive density data under enhanced delivery would strengthen the topical case; negative data would leave cosmetics as conditioning films.
Organ-culture replacement tests: Hachiya et al., 2009 KIT-blockade bleaching of human follicles is a ready system for adding back laboratory-made stem cell factor and measuring pigment or shaft length. A null result there would weaken replacement claims before any scalp randomized controlled trial.
Confounded cocktail studies: Mesotherapy mixes (VEGF analogues such as sh-Polypeptide-9, plant extracts, vitamins) cannot isolate SCF. Future single-ingredient, vehicle-controlled phototrichogram trials are the design that would actually move this evidence.

Conclusion

sh-Polypeptide-4 is a laboratory-made copy of human stem cell factor, a protein that turns on a matching receptor on pigment cells, hive-driving immune cells, and some follicle cells. University and cosmetics-company (Kao) laboratory work on human follicles shows that the control center of pattern-thinning hairs releases less of this protein than the control center of thicker, pigmented hairs, and that blocking the receptor bleaches hair in culture. Those findings motivate replacement. They do not show that a leave-on serum restores density.

The only substantial human exposure to laboratory-made stem cell factor has been injected pharmaceutical doses used to move blood-forming cells. Several of those studies were sponsored by Amgen, the injection’s manufacturer. They documented emptying of the cells that drive hives, hive-like injection reactions, and, in some people, extra pigment cells in the skin. No published trial has counted scalp hairs after topical sh-Polypeptide-4. Cosmetic labels list it as a conditioner, often mixed with other laboratory growth-factor copies, at undisclosed amounts. A protein of this size has little unaided reason to cross intact skin.

For a longevity-minded adult already willing to use inconvenient hair protocols, the molecule is a biologically interesting add-on with a pigment-cell rationale and a hive-reaction safety signal from a different route. It is not a stand-in for treatments that have hair-count trials. Uncertainty is the honest center of this evidence base.

Top - Benefits - Risks - Protocol

sh-Polypeptide-4 for Hair Regrowth

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Hair and cutaneous pigment-cell support

Speculative 🟨

Increased scalp hair density

Anagen support via epithelial KIT

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Mast-cell degranulation with wheal-and-flare (a raised itchy bump with surrounding redness) and anaphylactoid (anaphylaxis-like, non-allergic) reactions

Medium 🟥 🟥

Low 🟥

Unwanted cutaneous hyperpigmentation

Speculative 🟨

Promotion of KIT-driven cell clones

Immunogenicity of E. coli recombinant protein

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion